Increasing Prevalence of Orthopedic Diseases and Chronic Pain
The rising prevalence of orthopedic disorders, such as arthritis, elbow pain, fibromyalgia, and osteoporosis, coupled with the associated chronic pain, are the primary factors responsible for the growth of the opioids market. Opioids play a vital role in the acute post-operative settings, to provide adequate analgesia. As per the Center for Disease Control and Prevention, over 30 million patients are affected by osteoarthritis each year, in the United States. In addition, the International Osteoporosis Foundation states that osteoporosis is considered one of the most serious public health concerns among women, affecting more than 30% of the population each year, in the United States and Europe, and leading to multiple fractures. Opioid therapy remains the mainstay in the orthopedics treatments of patients with moderate to severe pain, thus driving the growth of the market studied.
The other driving factors include - shifting focus from intermediate release to extended release formulations of opioids, increasing focus on abuse-deterrent formulations by generic manufacturers, and growing palliative care facilities.
Prescription Drug Abuse to Hinder the Market’s Growth
The increased prescription of opioid medications has led to the widespread misuse of both prescription and non-prescription opioids, which leads to its highly addictive nature. According to the US Department of Health and Human Services, in 2016, more than 11 million people misused the prescription opioids, including nearly two million who misused the prescription drug for the first time. The Canadian Institute of Health Information reported that in 2016, there were more than 2,800 opioid-related deaths in the country. In Asia-Pacific, countries like Japan do not cover opioids under insurance, thereby leading to concerns of drug abuse in the region. Thus, the aforementioned factors are restraining the market’s growth, globally.
The other factors impeding the market studied include the advent and legalization of cannabis as an alternative to opioids.
The United States is Poised to Dominate the Opioids Market
Due to rising adoption of opioids and growing geriatric population, particularly in the United States, North America is expected to dominate the market studied. The country is affected by the over-consumption of prescription and over-the-counter opioids. A large section of the US population indicates an increased dependence over oxycodone, hydrocodone, and morphine, which are being commonly prescribed to treat pain. With high usage and demand, the FDA requires companies to provide more training to prescribers, in order to help prevent abuse and addiction. Over the forecast period, with the rise in hospitalization and better healthcare facilities, the United States is expected to be major revenue generating region for the opioids market.
Key Developments in the Market
- June 2018 - Nektar Therapeutics submitted a new drug application (NDA) for NKTR-181, for the treatment of chronic low back pain.
Reasons to Purchase this Report
- Current and future of opioids market in the developed and emerging markets
- Analysis of various perspectives of the market, with the help of Porter’s five forces analysis
- The segment that is expected to dominate the market
- The regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, market shares, and strategies employed by the major market players
- 3 months analyst support, along with the Market Estimate sheet (in excel)
This report can be customized to meet your requirements. Please connect with our Customer Service Team, who will ensure that you to get a report that suits your needs.
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Products and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Rising Prevalence of Orthopedic Diseases and Chronic Pain
6.1.2 Inclination toward Extended Release Formulations from the Immediate Release of Opioids
6.1.3 Rising Focus on Abuse-deterrent Formulation (ADF) by Generic Manufacturers
6.1.4 Growing Palliative Care Facilities
6.2 Market Restraints
6.2.1 Advent and Legalization of Cannabis as an Alternative to Opioids
6.2.2 Prescription Drug Abuse
6.4 Key Challenges
7. Market Segmentation
7.1 By Product Type
7.2 By Receptor Binding
7.2.1 Strong Agonist
7.2.2 Mild to Moderate Agonist
7.2.3 Mixed Receptor Reaction
7.3 By Application
7.3.1 Pain Management
220.127.116.11 Cancer Pain
18.104.22.168 Neuropathic Pain
22.214.171.124 Osteoarthritis Pain
7.3.2 Cold and Cough
7.4 By Geography
7.4.1 North America
126.96.36.199 United States
188.8.131.52 United Kingdom
184.108.40.206 Rest of Europe
220.127.116.11 South Korea
18.104.22.168 Rest of Asia-Pacific
7.4.4 Middle East & Africa
22.214.171.124 South Africa
126.96.36.199 Rest of Middle East & Africa
7.4.5 South America
188.8.131.52 Rest of South America
8. Competitive Landscape
8.1 Merger and Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Product Launches
9. Key Players
9.2 Egalet Corporation
9.3 Endo Pharmaceuticals Inc.
9.4 Janssen Pharmaceuticals Inc.
9.6 Pfizer Inc.
9.7 Purdue Pharma LP
9.8 Qrxpharma Limited
9.9 Sun Pharmaceutical Industries Ltd
9.10 Teva Pharmaceutical Industries Ltd
* List Not Exhaustive
10. Future of the Market
- Egalet Corporation
- Endo Pharmaceuticals Inc.
- Janssen Pharmaceuticals Inc.
- Pfizer Inc.
- Purdue Pharma LP
- Qrxpharma Limited
- Sun Pharmaceutical Industries Ltd
- Teva Pharmaceutical Industries Ltd